- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Boehringer Ingelheim: Shashank Deshpande to lead Human Pharma business unit, Carinne Brouillon to retire
Ingelheim: Boehringer Ingelheim has announced that Shashank Deshpande, member of the Board of Managing Directors with responsibility for the Animal Health Business Unit, has been appointed to lead the Human Pharma Business Unit, effective October 1, 2024. Shashank Deshpande joined the Board of Managing Directors on September 1, 2023.
This came after Carinne Brouillon, member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit, has informed the Shareholders of her intention to retire from the company per October 1, 2024.
Dr. Armin Wiesler, Regional Managing Director and Head of Animal Health for Southeast Asia, Korea, Australia and New Zealand has been appointed a member of the Board of Managing Directors, effective October 1, 2024. He will succeed Shashank Deshpande to lead the Animal Health Business Unit from this date.
Christian Boehringer, Chairman of the Shareholders’ Committee commented, “I would like to thank Carinne for her leadership and for transforming our Human Pharma business to prepare the organization to launch our rich pipeline in the coming years. Her collegiality, positivity and patient-first mindset were felt throughout our organization.”
Hubertus von Baumbach, Chairman of the Board of Managing Directors added, “I want to thank Shashank for accepting his new role. His Board experience, longstanding leadership in our two largest human pharma markets and his pharma marketing background make him an excellent successor to Carinne, who I wish all the best for the future. I also welcome Armin to our Board. His animal health industry knowledge and deep commercial understanding make him well prepared to continue the transformational work Shashank successfully started in Animal Health.”
Shashank Deshpande joined Boehringer Ingelheim in 2012. Prior to his current Board mandate, he was Country Managing Director in Japan. Earlier, he held human pharma leadership and marketing positions in Japan and Germany. Shashank Deshpande is a highly experienced leader, with a strong business background, who lived and worked across Asia, Europe and North America. He holds a Master’s degree in Business Administration from the University of Hamburg, Germany.
Armin Wiesler joined Boehringer Ingelheim in 2008. Prior to his regional leadership role since 2021, he performed local, regional and global roles in corporate strategy and development, human pharma marketing and animal health. Armin Wiesler was a General Manager in Thailand, worked at Boehringer’s US headquarters and spent six years in corporate roles in Ingelheim. Dr. Wiesler holds a Doctorate and a Master’s degree in Economics from the University of Freiburg, Germany.
Read Also: Alembic Pharma secures USFDA approval for Dabigatran Etexilate Capsules
The Company was founded in 1885. The Company serves over 130 markets in the two business units Human Pharma and Animal Health.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751